Breaking News Instant updates and real-time market news.

YHOO

Yahoo

$41.68

-0.11 (-0.26%)

, MANH

Manhattan Associates

$59.01

1.105 (1.91%)

17:47
10/18/16
10/18
17:47
10/18/16
17:47

On The Fly: After Hours Movers

UP AFTER EARNINGS: Yahoo (YHOO), up 1.4%. DOWN AFTER EARNINGS: Manhattan Associates (MANH), down 10.2%... Cree (CREE), down 9.5%... Intel (INTC), down 5.3%... Intuitive Surgical (ISRG), down 2.7%... Linear Technology (LLTC), down 1.5%... Interactive Brokers (IBKR), down 0.5%. ALSO LOWER: Meridian Bioscience (VIVO), down 10.2% after the company provided revenue guidance for the fourth quarter, fiscal 2016, and fiscal 2017... Sunesis (SNSS), down 6.9% after it filed to sell common stock and preferred stock... Puma Biotechnology (PBYI), down 4.8% after it filed to sell $150M in common stock.

YHOO

Yahoo

$41.68

-0.11 (-0.26%)

MANH

Manhattan Associates

$59.01

1.105 (1.91%)

CREE

Cree

$25.20

0.4 (1.61%)

INTC

Intel

$37.75

0.46 (1.23%)

ISRG

Intuitive Surgical

$721.73

12.29 (1.73%)

LLTC

Linear Technology

$58.94

-0.04 (-0.07%)

IBKR

Interactive Brokers

$35.68

0.47 (1.33%)

VIVO

Meridian Bioscience

$18.65

0.05 (0.27%)

SNSS

Sunesis

$4.07

-0.12 (-2.86%)

PBYI

Puma Biotechnology

$52.65

0.35 (0.67%)

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 20

    Oct

  • 06

    Nov

  • 09

    Nov

  • 14

    Nov

  • 15

    Nov

  • 16

    Nov

  • 17

    Nov

  • 29

    Nov

  • 19

    Oct

  • 20

    Oct

YHOO Yahoo
$41.68

-0.11 (-0.26%)

10/18/16
10/18/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: Yahoo (YHOO) downgraded to Hold from Buy at Needham with analyst Laura Martin saying shares now trade above her previous $40 price target. 2. Chipotle (CMG) downgraded to Underperform from Market Perform at Raymond James with analyst Brian Vaccaro saying he believes the lost sales, still down 15-20% after the initial E.coli incident, could prove to be permanent and reflect the "new normal," increasing downside risk in the stock. 3. Prudential (PRU) downgraded to Market Perform from Outperform at FBR Capital with analyst Randy Binner saying he's taking some risk off the table ahead of the third quarter earnings reports. 4. DDR Corp. (DDR) downgraded to Neutral from Outperform at Boenning & Scattergood with analyst Floris van Dijkum saying DDR could suffer higher than expected dilution due to asset sales like the recently closed upstate New York portfolio and said there could be more downward pressure on NAV based on further disposals. 5. Carrizo Oil & Gas (CRZO) downgraded to Neutral from Buy at Goldman analyst John Nelson citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/18/16
NEED
10/18/16
DOWNGRADE
NEED
Hold
Yahoo downgraded to Hold from Buy at Needham
Needham analyst Laura Martin downgraded Yahoo to Hold saying shares now trade above her previous $40 price target, she worries Verizon (VZ) will walk away or renegotiate the acquisition price lower due to the 2014 hacking event, and lowered FY16 estimates to the low end of guidance.
09/28/16
SBSH
09/28/16
NO CHANGE
SBSH
Buy
Citi hopes Disney does not acquire Twitter
Citi analyst Jason Bazinet lays out four reasons for why he doesn't like Disney (DIS) pursuing an acquisition of Twitter (TWTR). Going back 15 years, the analyst can't think of a single web-based property that was successfully acquired by a traditional media firm. Two, he calls Twitter trends "troubling." Three, Bazinet estimates a cash offer would lower Disney's stock by $5 per share while an equity offer would drop its stock by $9. Four, the analyst feels it is unclear how Disney's content will help Twitter. Bazinet thinks both Yahoo (YHOO) and Twitter lost "significant money" when they streamed NFL content over the web. The analyst hopes Twitter is acquired by somebody other than Disney. He keeps a Buy rating on Disney shares. Both Loop Capital and Mizuho this morning downgraded Twitter to sell ratings.
09/23/16
BOFA
09/23/16
NO CHANGE
Target $55
BOFA
Buy
BofA thinks Verizon deal stays on track despite Yahoo data breach
Bank of America Merrill Lynch analyst Justin Post said that Yahoo's (YHOO) disclosure of the massive data breach impacting over 500M of its users is clearly a negative for the company that could result in email account closures, but he does not anticipate a major impact on Yahoo's business related to this breach, citing as evidence the fact that he is not aware of any significant business impairment or financial liability related to security breaches at LinkedIn (LNKD) in 2012 and at eBay (EBAY) in 2014. Post adds that the Target (TGT) data breach, which did include credit card info, is not directly comparable to Yahoo's breach. For Verizon (VZ) to back out of its acquisition agreement, Post thinks the company would need to assume Yahoo acted in bad faith during negotiations and that the Yahoo asset is impaired or comes with significant liability, neither of which he sees as being the case. The analyst keeps a Buy rating on Yahoo and bumped his target on the shares to $55 from $53, citing an increased price target on Alibaba (BABA) that a peer at the firm recently set.
MANH Manhattan Associates
$59.01

1.105 (1.91%)

10/13/16
BMUR
10/13/16
NO CHANGE
Target $75
BMUR
Buy
Manhattan Associates well positioned for solid quarter, says Brean Capital
Brean Capital analyst Yun Kim said checks on the industry fundamentals show a steady positive demand environment. The analyst believes Manhattan Associates remains well positioned to deliver yet another solid quarter including top line growth and improving margin leverage. Kim reiterated his Buy rating and $75 price target on Manhattan Associates shares.
08/02/16
BMUR
08/02/16
NO CHANGE
Target $75
BMUR
Buy
Manhattan Associates CFO rehire a positive, says Brean Capital
Brean Capital noted Manhattan Associates rehired Dennis Story as CFO and views it as positive for the company. The firm noted he resigned for family related issues, but he had been a long time member of the executive team and a key contributor to the company's consistent financial performance. Brean Capital reiterated its Buy rating and $75 price target on Manhattan Associates shares.
07/20/16
BMUR
07/20/16
NO CHANGE
Target $75
BMUR
Buy
Manhattan Associates reports 'typical solid' performance, says Brean Capital
Brean Capital called Manhattan Associates' Q2 results a typical solid performance. The firm said the shares reflect the company's exceptional consistency in its sales execution and could command higher valuation multiples as the company continues to show solid, consistent execution and improving margins. Brean Capital reiterated its Buy rating and $75 price target on Manhattan Associates shares.
07/12/16
RAJA
07/12/16
NO CHANGE
Target $74
RAJA
Outperform
Raymond James a bit more cautious on Manhattan's software license business
Raymond James analyst Terry Tillman has grown a bit more cautious on Manhattan Associates' more volatile software license business and believes Brexit and broader macro concerns could be a temporary headwind in close rates. As a result, Tillman lowered his 2016 software license estimate to 4.5% growth from 7.5% growth and lowered 2016 earnings by a penny to $1.75. The analyst continues to rate Manhattan Associates an Outperform given double digit top-line growth and 20%-30% earnings growth.
CREE Cree
$25.20

0.4 (1.61%)

08/25/16
08/25/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cree (CREE) initiated with a Buy at Roth Capital. 2. Reynolds American (RAI) initiated with a Neutral at UBS. 3. Twilio (TWLO) initiated with a Hold at Argus. 4. Phillips 66 Partners (PSXP) initiated with a Neutral at Goldman. 5. WD-40 (WDFC) initiated with a Hold at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/16
WILL
09/30/16
INITIATION
Target $23
WILL
Hold
Cree initiated with a Hold at Williams Capital
Williams Capital analyst Cynthia Motz initiated Cree with a Hold and a $23 price target.
08/17/16
NORL
08/17/16
DOWNGRADE
NORL
Market Perform
Cree downgraded to Market Perform from Outperform at Northland
08/24/16
ROTH
08/24/16
INITIATION
Target $34
ROTH
Buy
Cree initiated with a Buy at Roth Capital
Roth Capital analyst Craig Irwin initiated Cree with a Buy and $34 price target saying management is working to strategically reposition the company for accelerating growth in general lighting markets, and expects both revenue and profit acceleration as Wolfspeed proceeds are redeployed.
INTC Intel
$37.75

0.46 (1.23%)

10/14/16
WELS
10/14/16
NO CHANGE
WELS
Intel results likely to be boosted by positive catalysts, says Wells Fargo
Wells Fargo thinks that Intel's (INTC) September quarter report and December quarter guidance will be boosted by several positive catalysts, including signs of improving PC demand, solid revenue momentum at its Data Center Group, and ramping sales of modems for Apple's (AAPL) iPhone 7. The firm keeps a $40-$50 price target on Intel and continues to identify it as a top pick.
10/18/16
LEHM
10/18/16
UPGRADE
Target $45
LEHM
Overweight
Intel upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Blayne Curtis upgraded Intel (INTC) to Overweight citing better PC trends and a "compelling relative valuation." The company is positioned to return to "sustainable growth" amid better computer trends and double-digit server growth, Curtis tells investors in a research note. He raised his price target for Intel shares to $45 from $38. The chipmaker closed yesterday down 16c to $37.29. Curtis this morning also downgraded shares of Cypress Semiconductor (CY) to Equal Weight.
10/18/16
10/18/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Intel (INTC) upgraded to Overweight from Equal Weight at Barclays with analyst Blayne Curtis citing better PC trends and a "compelling relative valuation." 2. Ruth's Hospitality (RUTH was upgraded to Outperform from Market Perform at Raymond James and the firm upgraded Darden (DRI) to Market Perform from Underperform. 3. Cousins Properties (CUZ) upgraded to Hold from Sell at Stifel with analyst John Guinee citing valuation. 4. FirstEnergy (FE) upgraded to Buy from Hold at Evercore ISI and to Neutral from Sell at Citi. 5. Prologis (PLD) upgraded to Equalweight from Underweight at Capital One and to Buy from Hold at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
COWN
10/06/16
NO CHANGE
Target $80
COWN
Outperform
Cowen says to buy KLA-Tencor following merger agreement termination
Cowen analyst Timothy Arcuri said the KLA-Tencor (KLAC) merger with Lam Research (LRCX) was called off as expected. He said it was consistent with his assessment and believes Intel (INTC) was the culprit. The companies cited review of options amid recent ant-trust agency feedback. Arcuri said he continues to like Lam Research but prefers KLA-Tencor as he sees it as one of the only semi companies with roughly 30% upside. Arcuri maintained his Outperform rating and $80 price target on KLA-Tencor shares.
ISRG Intuitive Surgical
$721.73

12.29 (1.73%)

10/13/16
WELS
10/13/16
INITIATION
WELS
Outperform
Intuitive Surgical initiated with an Outperform at Wells Fargo
Wells Fargo analyst Larry Biegelsen started Intuitive Surgical with an Outperform rating and $815-$825 price target range. The analyst expects continued adoption of hernia repair and colorectal procedures to drive "strong growth" in the United States and views the company's international opportunity as underappreciated. Biegelsen sees "several reasons" for why Intuitive's share outperformance to continue.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $779
SBSH
Buy
Intuitive Surgical procedure upside looks likely, says Citi
Following his firm's semi-annual urology survey and gynecology survey, Citi analyst Amit Hazan believes more procedure upside for Intuitive Surgical looks likely. The results point to continued strength in Intuitive's legacy categories that make up nearly 70% of its U.S. procedures, Hazan tells investors in a research note. He keeps a Buy rating on the shares with a $779 price target.
09/19/16
LEER
09/19/16
NO CHANGE
Target $780
LEER
Outperform
Leerink positive on Intuitive Surgical's hernia opportunity
Leerink analyst Richard Newitter says he left this weekend's Annual Global Symposium on Robotic-Assisted and Minimally Invasive Hernia Repair "incrementally more positive" on the adoption outlook for Intuitive Surgical's robotic hernia category. Hernia can remain a source of upside for the company's gen surgery division, Newitter tells investors in a research note. He reiterates an Outperform rating on the shares with a $780 price target.
09/15/16
SBSH
09/15/16
NO CHANGE
SBSH
Buy
New prostate study a positive for Intuitive Surgical, says Citi
Citi analyst Amit Hazan noted that a new study published in the New England Journal of Medicine found no difference in mortality between prostrate cancer patients treated with surgery or radiation and those placed on active monitoring after 10 years. However, men assigned to active monitoring were significantly more likely to have metastatic disease, Hazan highlighted, calling the study a positive for Intuitive Surgical, as it may help doctors "swing the pendulum" back to treatment. The analyst, who thinks Intuitive's da Vinci Prostatectomy procedures can grow above incidence rates for several years, keeps a Buy rating on the stock.
LLTC Linear Technology
$58.94

-0.04 (-0.07%)

10/17/16
OPCO
10/17/16
DOWNGRADE
OPCO
Perform
Linear Technology downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Rick Schafer downgraded Linear Technology (LLTC) to Perform citing the company's upcoming merger with Analog Devices (ADI). The analyst sees "no obvious regulatory hurdles."
09/06/16
SBSH
09/06/16
NO CHANGE
SBSH
Citi thinks Texas Instruments was other bidder for Linear
Citi analyst Christopher Danely points out that Analog Devices (ADI), in its S-4 registration for the Linear Technology (LLTC) acquisition, revealed a competitive bid for Linear from another party. The analyst believes Texas Instruments (TXN) was the other party since it is the only other analog company with enough size to do an acquisition of Linear's size.
08/18/16
RHCO
08/18/16
NO CHANGE
RHCO
Analog Devices guidance conservative, says SunTrust
SunTrust analyst William Stein says that Analog Devices (ADI) reported "great results," and provided "conservative" Q3 guidance. He expects the company to raise its guidance next quarter, and predicts that its Q3 EPS will beat expectations in the wake of its acquisition of Linerar Technology (LLTC). Stein keeps an $80 price target and Buy rating on Analog Devices.
07/28/16
UBSW
07/28/16
UPGRADE
Target $62
UBSW
Neutral
Linear Technology upgraded to Neutral from Sell at UBS
UBS upgraded Linear Technology (LLTC) to Neutral from Sell and raised it price target to $62 from $42 on shares after Analog Devices (ADI) agreed to acquire the company for $46 per share in cash and 0.2321 of a share of Analog Devices common stock per share.
IBKR Interactive Brokers
$35.68

0.47 (1.33%)

03/22/16
RHCO
03/22/16
INITIATION
Target $40
RHCO
Neutral
Interactive Brokers initiated with a Neutral at SunTrust
SunTrust analyst initiated Douglas Mewhirter initiated Interactive Brokers with a Neutral rating and $40 price target.
05/12/16
BUCK
05/12/16
INITIATION
Target $38
BUCK
Neutral
Interactive Brokers initiated with a Neutral at Buckingham
Target $38.
01/12/16
01/12/16
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Apple (AAPL) downgraded to Negative from Mixed at OTR Global... Asbury Automotive (ABG) downgraded to Hold from Buy at Craig-Hallum... AvalonBay (AVB) downgraded to Market Perform from Outperform at Cowen... BHP Billiton (BHP) downgraded to Underweight from Equal Weight at Barclays... Canadian Natural (CNQ) downgraded to Equal Weight from Overweight at Morgan Stanley... Cloud Peak (CLD) downgraded to Underweight from Equal Weight at Barclays... Comerica (CMA) downgraded to Underperform from Buy at BofA/Merrill... Concho Resources (CXO) downgraded to Hold from Buy at Jefferies... DDR Corp. (DDR) downgraded to Hold from Buy at Jefferies... DHT Holdings (DHT) downgraded to Neutral from Overweight at JPMorgan... Diageo (DEO) downgraded to Hold from Buy at Stifel... E-Trade (ETFC) downgraded to Buy from Conviction Buy at Goldman... EQT Corporation (EQT) downgraded to Hold from Buy at Jefferies... Encana (ECA) downgraded to Equal Weight from Overweight at Morgan Stanley... Essex Property Trust (ESS) downgraded to Market Perform from Outperform at Cowen... Euronav NV (EURN) downgraded to Neutral from Overweight at JPMorgan... F5 Networks (FFIV) downgraded to Hold from Buy at Deutsche Bank... Freeport McMoRan (FCX) downgraded to Hold from Buy at Jefferies... Great Plains Energy (GXP) downgraded to Neutral from Buy at BofA/Merrill... HCP (HCP) downgraded to Underperform from Hold at Jefferies... HeartWare (HTWR) downgraded to Neutral from Overweight at JPMorgan... InterContinental (IHG) downgraded to Neutral from Buy at Citi... Interactive Brokers (IBKR) downgraded to Sell from Neutral at Goldman... KNOT Offshore Partners (KNOP) downgraded to Neutral from Buy at Citi... LPL Financial (LPLA) downgraded to Sell from Neutral at Citi... Laclede (LG) downgraded to Underweight from Equal Weight at Morgan Stanley... Lazard (LAZ) downgraded to Neutral from Buy at Goldman... Liberty Property (LPT) downgraded to Market Perform from Outperform at Cowen... Marathon Oil (MRO) downgraded to Equal Weight from Overweight at Morgan Stanley... McKesson (MCK) downgraded to Market Perform from Outperform at Raymond James... Mead Johnson (MJN) downgraded to Neutral from Buy at Nomura... Medical Properties Trust (MPW) downgraded to Hold from Buy at Jefferies... NGL Energy Partners (NGL) downgraded to Hold from Buy at Stifel... Occidental Petroleum (OXY) downgraded to Hold from Buy at Jefferies... Omega Healthcare (OHI) downgraded to Hold from Buy at Jefferies... Patterson-UTI (PTEN) downgraded to Neutral from Overweight at Simmons... Peabody (BTU) downgraded to Underperform from Hold at Jefferies... Penn National (PENN) downgraded to Neutral at BofA/Merrill... Pinnacle West (PNW) downgraded to Underweight from Equal Weight at Morgan Stanley... Pioneer Energy (PES) downgraded to Neutral from Overweight at Simmons... Progressive Waste (BIN) downgraded to In-Line from Outperform at Imperial Capital... Prosperity Bancshares (PB) downgraded to Underperform from Neutral at BofA/Merrill... Raymond James (RJF) downgraded to Neutral from Buy at Citi... Rent-A-Center (RCII) downgraded to Hold from Buy at BB&T... Roadrunner (RRTS) downgraded to Peer Perform from Outperform at Wolfe Research... Rose Rock Midstream (RRMS) downgraded to Equalweight from Overweight at Capital One... Rouse Properties (RSE) downgraded to Underperform from Neutral at BofA/Merrill... SABMiller (SBMRY) downgraded to Hold from Buy at Stifel ... Scientific Games (SGMS) downgraded to Underperform from Neutral at BofA/Merrill... Southern Copper (SCCO) downgraded to Equal Weight from Overweight at Barclays... Synergy Resources (SYRG) downgraded to Equal Weight from Overweight at Stephens... Taubman Centers (TCO) downgraded to Underperform from Hold at Jefferies... Teekay Tankers (TNK) downgraded to Underweight from Overweight at JPMorgan... Telenor (TELNY) downgraded to Underweight from Overweight at JPMorgan... UDR, Inc. (UDR) downgraded to Market Perform from Outperform at Cowen... Vedanta Resources (VDNRF) downgraded to Underperform from Hold at Jefferies... Western Gas Partners (WES) downgraded to Neutral from Buy at BofA/Merrill... Whiting Petroleum (WLL) downgraded to Underweight from Equal Weight at Morgan Stanley... Zurich Insurance (ZURVY) downgraded to Underweight from Neutral at JPMorgan.
03/22/16
RHCO
03/22/16
INITIATION
Target $40
RHCO
Neutral
Interactive Brokers initiated with a Neutral at SunTrust
Target $40.
VIVO Meridian Bioscience
$18.65

0.05 (0.27%)

07/29/16
HDLY
07/29/16
DOWNGRADE
HDLY
Neutral
Meridian Bioscience downgraded to Neutral from Buy at Hilliard Lyons
05/26/16
PIPR
05/26/16
NO CHANGE
PIPR
Piper sees limited impact from new European device tax rules
Piper Jaffray analyst William Quirk points out that the European Union announced it will issue new rules for medical devices and in vitro diagnostics in the near-to-mid term. The EU is looking to strengthen rules for clearing devices/tests for the market and increase existing device/test surveillance, Quirk tells investors in a research note. He believes the new rules should not inhibit well validated tests/devices from coming to market. As such, Quirk expects little impact to Piper's in vitro diagnostic coverage universe, namely Accelerate Diagnostics (AXDX), Becton Dickinson (BDX), Cepheid (CPHD), Hologic (HOLX), Quidel (QDEL) and Meridian Bioscience (VIVO).
03/28/16
HDLY
03/28/16
UPGRADE
HDLY
Buy
Meridian Bioscience upgraded to Buy from Neutral at Hilliard Lyons
03/22/16
PIPR
03/22/16
NO CHANGE
PIPR
Flu activity picked up in recent weeks, says Piper Jaffray
Piper Jaffray analyst William Quirk says flu activity began to ramp in recent weeks with the CDC reporting the percent of influenza-like illnesses per outpatient visit during week 10 was 3.7%, above the 2.3% average. With the Street expecting little Q1 improvement in flu activity, Quidel (QDEL) could report upside to revenue expectations, Quirk tells investors in a research note. Cepheid (CPHD) could also benefit, and flu trends are also positive for Becton Dickinson (BDX), Meridian Bioscience (VIVO) and Masimo (MASI), the analyst contends.
SNSS Sunesis
$4.07

-0.12 (-2.86%)

07/29/16
WELS
07/29/16
UPGRADE
WELS
Outperform
Sunesis upgraded on imrpoved outlook at Wells Fargo
As noted earlier, Wells Fargo upgraded Sunesis to Outperform from Market Perform. After meeting with the company's management, Wells analyst Jim Birchenough is more upbeat about the outlook for the company's SNS-062 Bruton's tyrosine kinase inhibitor. He is also bullish on the risk/reward ratio of its Qinprezo for relapsed/refractory acute myeloid leukemia. Target to $4.50-$5.50 from $1-$1.25.
07/29/16
WELS
07/29/16
UPGRADE
WELS
Outperform
Sunesis upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded Sunesis Pharmaceuticals to Outperform after meeting with the company and raised his price target range for the shares to $4.50-$5.50 from $1.00-$1.25. The analyst sees "limited downside risk and significant upside potential" given the company's opportunities with Qinprezo and SNS062.
07/29/16
WELS
07/29/16
UPGRADE
WELS
Outperform
Sunesis upgraded to Outperform from Market Perform at Wells Fargo
01/05/16
01/05/16
UPGRADE

On The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Agrium (AGU) upgraded to Neutral from Sell at Citi... Anadarko (APC) upgraded to Buy from Neutral at Citi... BNP Paribas (BNPQY) upgraded to Outperform from Sector Perform at RBC Capital... Baker Hughes (BHI) upgraded to Overweight from Sector Weight at KeyBanc... Banco Bilbao (BBVA) upgraded to Sector Perform from Underperform at RBC Capital... Beazer Homes (BZH) upgraded to Outperform from Sector Perform at FBN Securities... Canadian Natural (CNQ) upgraded to Buy from Neutral at Citi... Celanese (CE) upgraded to Buy from Neutral at Citi... Cimarex Energy (XEC) upgraded to Buy from Hold at Evercore ISI... Clean Energy (CLNE) upgraded to Market Perform from Underperform at Raymond James... Continental Resources (CLR) upgraded to Buy from Hold at Evercore ISI... Delek US (DK) upgraded to Buy on relative valuation at BofA/Merrill... Deutsche Bank (DB) upgraded to Outperform from Sector Perform at RBC Capital... EOG Resources (EOG) upgraded to Buy from Neutral at Citi... Eastman Chemical (EMN) upgraded to Buy from Neutral at Citi... Enviva (EVA) upgraded to Strong Buy from Outperform at Raymond James... Equinix (EQIX) upgraded to Buy from Hold at Stifel... FLIR Systems (FLIR) upgraded to Strong Buy from Outperform at Raymond James... First Solar (FSLR) upgraded to Buy, shares have 50% upside, says Goldman... Fresenius Medical (FMS) upgraded to Buy from Neutral at UBS... G-III Apparel (GIII) upgraded to Outperform from Market Perform at Telsey Advisory... Halliburton (HAL) upgraded to Overweight from Sector Weight at KeyBanc... HollyFrontier (HFC) upgraded to Buy from Underperform at BofA/Merrill... Home Bancshares (HOMB) upgraded to Outperform from Market Perform at Hovde Group... Inphi (IPHI) upgraded to Outperform from Market Perform at Northland... J.C. Penney (JCP) upgraded to Neutral from Sell at Citi... Juniper (JNPR) upgraded to Buy from Hold at Deutsche Bank... Lundbeck (HLUYY) upgraded to Overweight from Neutral at JPMorgan... M/I Homes (MHO) upgraded to Outperform from Sector Perform at FBN Securities... Marathon Petroleum (MPC) upgraded to Neutral from Underperform at BofA/Merrill... Meritage Homes (MTH) upgraded to Outperform from Sector Perform at FBN Securities... Navigant Consulting (NCI) upgraded to Outperform from Market Perform at William Blair... New York Community Bancorp (NYCB) upgraded to Buy from Neutral at Sterne Agee CRT... Oasis Petroleum (OAS) upgraded to Neutral from Sell at Citi... Puma (PMMAF) upgraded to Buy from Hold at Berenberg... RBS (RBS) upgraded to Outperform from Sector Perform at RBC Capital... Ramco-Gershenson (RPT) upgraded to Buy from Hold at Deutsche Bank... Silgan Holdings (SLGN) upgraded to Outperform from Neutral at Baird... Smith & Wesson (SWHC) upgraded to Buy from Hold at BB&T... Societe Generale (SCGLY) upgraded to Sector Perform from Underperform at RBC Capital... SolarEdge (SEDG) upgraded to Conviction Buy from Buy at Goldman... Spirit AeroSystems (SPR) upgraded to Outperform from Market Perform at Bernstein... Sunesis (SNSS) upgraded to Speculative Buy from Hold at Cantor... Swedbank (SWDBY) upgraded to Sector Perform from Underperform at RBC Capital... Tesco (TSCDY) upgraded to Buy from Hold at Deutsche Bank... Toll Brothers (TOL) upgraded to Sector Perform from Underperform at FBN Securities... Total System (TSS) upgraded to Neutral from Underperform at Credit Suisse... Wolverine World Wide (WWW) upgraded to Neutral from Underperform at Sterne Agee CRT... adidas (ADDYY) upgraded to Hold from Sell at Berenberg.
PBYI Puma Biotechnology
$52.65

0.35 (0.67%)

09/22/16
FBCO
09/22/16
NO CHANGE
Target $111
FBCO
Outperform
Puma Biotechnology price target raised to $111 from $54 at Credit Suisse
Credit Suisse analyst Kennen MacKay raised his price target for Puma Biotechnology by $57 to $111 after increasing his sales expectations for neratinib. The biotech focused on cancer treatment closed yesterday up $2.98 to $67.97. The FDA's acceptance of Puma's New Drug Application for neratinib for patients with early stage HER2-overexpressed/amplified breast cancer is a "key de-risking event," MacKay tells investors in a research note. Further, the analyst says his doctor checks suggest "improved physician sentiment" towards neratinib and growing awareness surrounding the use of Imodium prophylaxis to manage diarrhea. He keeps a Buy rating on shares of Puma Biotechnology.
09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
09/21/16
STFL
09/21/16
UPGRADE
STFL
Buy
Puma Biotechnology upgraded to Buy from Hold at Stifel
Stifel analyst Thomas Shrader upgraded Puma after it announced that the FDA had accepted for review the New Drug Application for neratinib in the extended adjuvant treatment. The analyst says that the news "is unusually important..due to procedural irregularities" in a trial. He adds that doctors are becoming more enthusiastic about the drug which meets a significant unmet need. He thinks that its safety issues "look to be under reasonable control," and he now thinks the drug has a 90% chance of being approved. Target to $88 from $61.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $88
SBSH
Buy
Citi expects Puma to be up at least 10%-15% on today's news
Citi analyst Yigal Nochomovitz views this morning's news that the FDA accepted Puma Biotechnology's New Drug Application for its lead product candidate PB272 as "perhaps the biggest derisking event" in the company's history. A broader set of investors could be inclined to take a position in the name now, Nochomovitz tells investors in a research note. The analyst recommends buying Puma shares on the news. He expects neratinib to be approved by the FDA next summer and expects the stock to be up at least 10%-15% on today's news. The analyst has a Buy rating on the shares with an $88 price target. Puma is up 9%, or $5.05, to $64 in pre-market trading.

TODAY'S FREE FLY STORIES

ANET

Arista Networks

$94.41

-1.35 (-1.41%)

, CSCO

Cisco

$30.06

0.11 (0.37%)

18:32
12/09/16
12/09
18:32
12/09/16
18:32
Hot Stocks
Arista Networks favored in ITC initial determination on four of six patents »

Arista Networks (ANET)…

ANET

Arista Networks

$94.41

-1.35 (-1.41%)

CSCO

Cisco

$30.06

0.11 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

TKTDY

Takata Corporation

$10.70

0.05 (0.47%)

18:22
12/09/16
12/09
18:22
12/09/16
18:22
Periodicals
U.S. DOT looks to accelerate pace of Takata air bag replacements, Reuters says »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DV

DeVry

$31.90

0.9 (2.90%)

18:17
12/09/16
12/09
18:17
12/09/16
18:17
Hot Stocks
Breaking Hot Stocks news story on DeVry »

International Value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

18:10
12/09/16
12/09
18:10
12/09/16
18:10
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Cornerstone OnDemand has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$0.12

-0.0014 (-1.17%)

18:03
12/09/16
12/09
18:03
12/09/16
18:03
Hot Stocks
NYSE MKT says CEL-SCI noncompliant with certain listing requirements »

CEL-SCI reported on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$89.00

0.68 (0.77%)

18:01
12/09/16
12/09
18:01
12/09/16
18:01
Periodicals
Exxon CEO Tillerson emerges as top candidate for secretary of state, WSJ says »

Exxon Mobil CEO Rex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$50.36

0.05 (0.10%)

17:58
12/09/16
12/09
17:58
12/09/16
17:58
Hot Stocks
H.B. Fuller announces restructuring, to eliminate, relocate 220 positions »

H.B. Fuller has announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$287.77

-1.77 (-0.61%)

17:53
12/09/16
12/09
17:53
12/09/16
17:53
Periodicals
Biogen looks like a bargain, Barron's reports »

Biogen trades at just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$40.40

0.63 (1.58%)

17:42
12/09/16
12/09
17:42
12/09/16
17:42
Periodicals
Sanofi to lay off 20% of U.S. diabetes, cardiovascular staff, Bloomberg says »

The layoffs include parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

17:38
12/09/16
12/09
17:38
12/09/16
17:38
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Investor Praesidium said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TACO

Del Taco

$14.75

-0.39 (-2.58%)

17:34
12/09/16
12/09
17:34
12/09/16
17:34
Hot Stocks
Breaking Hot Stocks news story on Del Taco »

PW Acquisitions cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 09

    Jan

  • 09

    Dec

UNVR

Univar

$26.36

0.54 (2.09%)

, BXLT

Baxalta

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Univar names Eric Foster chief information officer »

Univar (UNVR) named Eric…

UNVR

Univar

$26.36

0.54 (2.09%)

BXLT

Baxalta

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PARN

Parnell

$1.42

-0.0031 (-0.22%)

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Breaking Hot Stocks news story on Parnell 

Parnell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$20.81

0.2 (0.97%)

, NVRO

Nevro

$76.38

-1.88 (-2.40%)

17:24
12/09/16
12/09
17:24
12/09/16
17:24
Hot Stocks
Boston Scientific files patent infringement suit against Nevro »

Nevro (NVRO) announced…

BSX

Boston Scientific

$20.81

0.2 (0.97%)

NVRO

Nevro

$76.38

-1.88 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RTN

Raytheon

$146.30

0.14 (0.10%)

17:21
12/09/16
12/09
17:21
12/09/16
17:21
Hot Stocks
Raytheon awarded $101.9M government contract »

Raytheon Co., Goleta,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$8.77

-0.16 (-1.79%)

17:18
12/09/16
12/09
17:18
12/09/16
17:18
Hot Stocks
CEMEX receives subpoena from SEC regarding Foreign Corrupt Practices Act »

On December 9, 2016,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDEX

PRO-DEX

$4.48

0.034 (0.76%)

17:06
12/09/16
12/09
17:06
12/09/16
17:06
Syndicate
Breaking Syndicate news story on PRO-DEX »

PRO-DEX files $25M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFBX

Peoples Financial

$14.50

-0.5 (-3.33%)

17:02
12/09/16
12/09
17:02
12/09/16
17:02
Hot Stocks
Breaking Hot Stocks news story on Peoples Financial »

Jeffrey L. Gendell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QUIK

QuickLogic

$0.94

-0.0163 (-1.71%)

17:00
12/09/16
12/09
17:00
12/09/16
17:00
Syndicate
Breaking Syndicate news story on QuickLogic »

QuickLogic files $40M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STRZA

Starz

17:00
12/09/16
12/09
17:00
12/09/16
17:00
Hot Stocks
Breaking Hot Stocks news story on Starz »

Elliott Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEL

Belmond

16:55
12/09/16
12/09
16:55
12/09/16
16:55
Syndicate
Breaking Syndicate news story on Belmond »

Belmond files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PARN

Parnell

$1.42

-0.0031 (-0.22%)

16:55
12/09/16
12/09
16:55
12/09/16
16:55
Hot Stocks
Breaking Hot Stocks news story on Parnell »

Parnell trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$43.73

0.15 (0.34%)

, SHAK

Shake Shack

$38.08

0.82 (2.20%)

16:50
12/09/16
12/09
16:50
12/09/16
16:50
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Shake Shack »

Morgan Stanley reports…

MS

Morgan Stanley

$43.73

0.15 (0.34%)

SHAK

Shake Shack

$38.08

0.82 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

MS

Morgan Stanley

$43.73

0.15 (0.34%)

, LXFT

Luxoft

$54.40

-1.8 (-3.20%)

16:44
12/09/16
12/09
16:44
12/09/16
16:44
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Luxoft »

Morgan Stanley reports…

MS

Morgan Stanley

$43.73

0.15 (0.34%)

LXFT

Luxoft

$54.40

-1.8 (-3.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$50.36

0.05 (0.10%)

16:44
12/09/16
12/09
16:44
12/09/16
16:44
Hot Stocks
H.B. Fuller announces restructuring plan »

On December 7, H.B.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.